MeadowBrook Investment Advisors LLC Has $226,000 Stock Position in Lantheus Holdings, Inc. $LNTH

MeadowBrook Investment Advisors LLC grew its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 20.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,765 shares of the medical equipment provider’s stock after buying an additional 460 shares during the quarter. MeadowBrook Investment Advisors LLC’s holdings in Lantheus were worth $226,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. State of Michigan Retirement System boosted its holdings in shares of Lantheus by 0.6% in the first quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider’s stock worth $1,620,000 after buying an additional 100 shares during the period. Signaturefd LLC boosted its holdings in shares of Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 116 shares during the period. Intrust Bank NA boosted its holdings in shares of Lantheus by 2.9% in the first quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider’s stock worth $431,000 after buying an additional 125 shares during the period. Focus Financial Network Inc. boosted its holdings in shares of Lantheus by 4.0% in the second quarter. Focus Financial Network Inc. now owns 3,576 shares of the medical equipment provider’s stock worth $293,000 after buying an additional 136 shares during the period. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of Lantheus by 2.1% in the first quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider’s stock worth $653,000 after buying an additional 139 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Price Performance

NASDAQ LNTH opened at $55.88 on Thursday. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $3.80 billion, a PE ratio of 14.86 and a beta of 0.09. The company has a 50 day moving average price of $54.22 and a two-hundred day moving average price of $70.73. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $118.21.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. The firm had revenue of $92.51 million during the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. As a group, equities analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares in the company, valued at $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of Lantheus stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. This trade represents a 49.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 6,812,000 shares of company stock valued at $382,427,380 over the last quarter. Corporate insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on LNTH. Mizuho decreased their price target on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. JMP Securities decreased their price target on shares of Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a report on Thursday, August 7th. B. Riley decreased their price target on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a report on Tuesday, September 16th. Weiss Ratings cut shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. Finally, TD Cowen decreased their price target on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, September 15th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $74.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.